CYKLOKAPRON® 17 PATIENT COUNSELING INFORMATION

(tranexamic acid)

17 PATIENT COUNSELING INFORMATION

Thromboembolic Risk

Inform patients that CYKLOKAPRON may increase the risk of venous and arterial thrombosis or thromboembolism and to contact their healthcare provider for any signs or symptoms suggestive of thromboembolism.

Advise patients using hormonal contraception that combined use with CYKLOKAPRON may increase the risk for thromboembolic adverse reactions and to use effective alternative (nonhormonal) contraception during therapy with CYKLOKAPRON [see Warnings and Precautions (5.1), Drug Interactions (7.1), Use in Specific Populations (8.3)].

Seizures

Inform patients that CYKLOKAPRON may cause seizures and to contact their healthcare provider for any signs or symptoms suggestive of seizures [see Warnings and Precautions (5.3)].

Hypersensitivity Reactions

Inform patients that CYKLOKAPRON may cause hypersensitivity reactions and to contact their healthcare provider for any signs or symptoms of hypersensitivity reactions [see Warnings and Precautions (5.4)].

Visual Disturbances

Inform patients that CYKLOKAPRON can cause visual disturbance and that they should report any eye symptoms or change in their vision to their healthcare provider and to follow-up with an ophthalmologist for a complete ophthalmologic evaluation, including dilated retinal examination of the retina [see Warnings and Precautions (5.5)].

Risk of Driving and Operating Machinery

Inform patients that CYKLOKAPRON may cause dizziness, and that the patient should be cautioned about driving, operating machinery, or performing hazardous tasks while taking CYKLOKAPRON [see Warnings and Precautions (5.6)].

Find CYKLOKAPRON® medical information:

Find CYKLOKAPRON® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CYKLOKAPRON® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

17 PATIENT COUNSELING INFORMATION

17 PATIENT COUNSELING INFORMATION

Thromboembolic Risk

Inform patients that CYKLOKAPRON may increase the risk of venous and arterial thrombosis or thromboembolism and to contact their healthcare provider for any signs or symptoms suggestive of thromboembolism.

Advise patients using hormonal contraception that combined use with CYKLOKAPRON may increase the risk for thromboembolic adverse reactions and to use effective alternative (nonhormonal) contraception during therapy with CYKLOKAPRON [see Warnings and Precautions (5.1), Drug Interactions (7.1), Use in Specific Populations (8.3)].

Seizures

Inform patients that CYKLOKAPRON may cause seizures and to contact their healthcare provider for any signs or symptoms suggestive of seizures [see Warnings and Precautions (5.3)].

Hypersensitivity Reactions

Inform patients that CYKLOKAPRON may cause hypersensitivity reactions and to contact their healthcare provider for any signs or symptoms of hypersensitivity reactions [see Warnings and Precautions (5.4)].

Visual Disturbances

Inform patients that CYKLOKAPRON can cause visual disturbance and that they should report any eye symptoms or change in their vision to their healthcare provider and to follow-up with an ophthalmologist for a complete ophthalmologic evaluation, including dilated retinal examination of the retina [see Warnings and Precautions (5.5)].

Risk of Driving and Operating Machinery

Inform patients that CYKLOKAPRON may cause dizziness, and that the patient should be cautioned about driving, operating machinery, or performing hazardous tasks while taking CYKLOKAPRON [see Warnings and Precautions (5.6)].

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.